• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[轻度克罗恩病和轻度溃疡性结肠炎的有效治疗]

[Efficient treatment of mild Crohn's disease and mild ulcerative colitis].

作者信息

Rogler Gerhard

机构信息

Klinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz.

出版信息

Inn Med (Heidelb). 2025 Jan;66(1):15-21. doi: 10.1007/s00108-024-01840-x. Epub 2024 Dec 23.

DOI:10.1007/s00108-024-01840-x
PMID:39715834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11761793/
Abstract

The cornerstone of treatment for mild ulcerative colitis is still the oral or topical (rectal) application of aminosalicylates (5-ASA). 5‑ASA preparations are often only administered orally in mild ulcerative colitis. Study data show that in ulcerative proctitis and left-sided colitis, rectal 5‑ASA preparations are even more effective than oral administration. In a next step, steroid-containing topical therapies should be used. Topical steroids such as budesonide are also primarily used in mild Crohn's disease. However, it is controversial whether treatment is necessary in symptom-free patients. There is still a lack of evidence to prove that more aggressive treatment (using immunosuppressants, biologics or small molecules) has a long-term benefit in these patients. Most guidelines are critical of the use of 5‑ASA in mild Crohn's disease. Nevertheless, there is some evidence for sufficiently high-dose treatment with 5‑ASA, although one must be aware of its limited effectiveness. However, there is clear evidence for the postoperative use of 5‑ASA in cases of mild recurrence.

摘要

轻度溃疡性结肠炎的治疗基石仍然是口服或局部(直肠)应用氨基水杨酸酯(5-ASA)。在轻度溃疡性结肠炎中,5-ASA制剂通常仅口服给药。研究数据表明,在溃疡性直肠炎和左侧结肠炎中,直肠用5-ASA制剂比口服给药更有效。下一步应使用含类固醇的局部治疗。布地奈德等局部类固醇也主要用于轻度克罗恩病。然而,无症状患者是否需要治疗存在争议。仍然缺乏证据证明更积极的治疗(使用免疫抑制剂、生物制剂或小分子药物)对这些患者有长期益处。大多数指南对在轻度克罗恩病中使用5-ASA持批评态度。尽管如此,有一些证据支持用足够高剂量的5-ASA进行治疗,不过必须意识到其有效性有限。然而,有明确证据表明在轻度复发的情况下术后使用5-ASA。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e1/11761793/f09792453e78/108_2024_1840_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e1/11761793/caa0886a5af9/108_2024_1840_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e1/11761793/f09792453e78/108_2024_1840_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e1/11761793/caa0886a5af9/108_2024_1840_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07e1/11761793/f09792453e78/108_2024_1840_Fig2_HTML.jpg

相似文献

1
[Efficient treatment of mild Crohn's disease and mild ulcerative colitis].[轻度克罗恩病和轻度溃疡性结肠炎的有效治疗]
Inn Med (Heidelb). 2025 Jan;66(1):15-21. doi: 10.1007/s00108-024-01840-x. Epub 2024 Dec 23.
2
Topical therapy is underused in patients with ulcerative colitis.局部治疗在溃疡性结肠炎患者中未得到充分应用。
J Crohns Colitis. 2014 Jan;8(1):56-63. doi: 10.1016/j.crohns.2013.03.005. Epub 2013 Apr 6.
3
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.溃疡性直肠炎和溃疡性直肠乙状结肠炎患者的基线口服5-氨基水杨酸使用情况以及布地奈德泡沫剂的疗效和安全性:两项3期研究的分析
Inflamm Bowel Dis. 2016 Aug;22(8):1881-6. doi: 10.1097/MIB.0000000000000860.
4
Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.口服缓释美沙拉嗪:其在溃疡性结肠炎和克罗恩病中的应用综述
Drugs. 1999 Mar;57(3):383-408. doi: 10.2165/00003495-199957030-00013.
5
Topical therapies in inflammatory bowel disease.炎症性肠病的局部治疗。
Digestion. 2012;86 Suppl 1:36-44. doi: 10.1159/000341947. Epub 2012 Oct 5.
6
Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.新发溃疡性结肠炎和溃疡性直肠炎的治疗:一项回顾性研究。
Aliment Pharmacol Ther. 2012 Aug;36(3):248-56. doi: 10.1111/j.1365-2036.2012.05175.x. Epub 2012 Jun 12.
7
Oral budesonide for induction of remission in ulcerative colitis.口服布地奈德诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2015 Oct 26;2015(10):CD007698. doi: 10.1002/14651858.CD007698.pub3.
8
Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?轻至中度克罗恩病的初始治疗:美沙拉嗪还是布地奈德?
Rev Gastroenterol Disord. 2002;2 Suppl 2:S9-15.
9
Oral budesonide for induction of remission in ulcerative colitis.口服布地奈德诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2010 Oct 6(10):CD007698. doi: 10.1002/14651858.CD007698.pub2.
10
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.比较药物治疗轻中度溃疡性结肠炎的疗效和耐受性:系统评价和网络荟萃分析。
Lancet Gastroenterol Hepatol. 2018 Nov;3(11):742-753. doi: 10.1016/S2468-1253(18)30231-0. Epub 2018 Aug 17.

本文引用的文献

1
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus.轻度至中度溃疡性结肠炎的实用管理:国际专家共识。
Expert Rev Gastroenterol Hepatol. 2024 Aug;18(8):421-430. doi: 10.1080/17474124.2024.2397650. Epub 2024 Sep 3.
2
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.欧洲克罗恩病治疗指南:药物治疗
J Crohns Colitis. 2024 Oct 15;18(10):1531-1555. doi: 10.1093/ecco-jcc/jjae091.
3
Design of Clinical Trials for Mild to Moderate Crohn's Disease.轻至中度克罗恩病临床试验的设计
Gastroenterology. 2022 Jun;162(7):1800-1814.e1. doi: 10.1053/j.gastro.2022.02.036. Epub 2022 Feb 28.
4
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.欧洲克罗恩病和结肠炎组织(ECCO)溃疡性结肠炎治疗指南:药物治疗
J Crohns Colitis. 2022 Jan 28;16(1):2-17. doi: 10.1093/ecco-jcc/jjab178.
5
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis.口服、局部或联合口服和局部 5-氨基水杨酸治疗溃疡性结肠炎的疗效:系统评价和网络荟萃分析。
J Crohns Colitis. 2021 Jul 5;15(7):1184-1196. doi: 10.1093/ecco-jcc/jjab010.
6
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸用于诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2020 Aug 12;8(8):CD000543. doi: 10.1002/14651858.CD000543.pub5.
7
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.英国胃肠病学会成人炎症性肠病管理共识指南。
Gut. 2019 Dec;68(Suppl 3):s1-s106. doi: 10.1136/gutjnl-2019-318484. Epub 2019 Sep 27.
8
Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis.维持克罗恩病手术诱导缓解的干预措施:一项网状Meta分析
Cochrane Database Syst Rev. 2019 Sep 12;9(9):CD013210. doi: 10.1002/14651858.CD013210.pub2.
9
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.布地奈德 MMX 与美沙拉嗪治疗活动期轻中度溃疡性结肠炎的比较评估:系统评价和网络荟萃分析。
Br J Clin Pharmacol. 2019 Oct;85(10):2244-2254. doi: 10.1111/bcp.14051. Epub 2019 Jul 31.
10
Budesonide for the Induction and Maintenance of Remission in Crohn's Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration.布地奈德用于诱导和维持克罗恩病缓解:Cochrane协作网的系统评价和荟萃分析
J Can Assoc Gastroenterol. 2018 Dec;1(4):159-173. doi: 10.1093/jcag/gwy018. Epub 2018 May 24.